- MACK Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
8-K Filing Data
Merrimack Pharmaceuticals (MACK) 8-K3 Aug 22Merrimack provides Ipsen report of results from Phase III RESILIENT trial evaluating Onivyde® in second-line monotherapy for small cell lung cancerFinancial data
Company Profile